Navigation Links
Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria
Date:2/24/2010

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics.  Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products.  However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About PharmAthene, Inc.

PharmAthene
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
3. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
6. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
7. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
8. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
11. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... 2015 What can be expected ... are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... tables, charts, and graphs. Discover the most lucrative areas ... new study lets you assess forecasted sales at overall ...
(Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... 2012 Escalon Medical Corp.,s (Nasdaq Market: ESMC) subsidiary, ... successfully completed the outsourced manufacturing of its HbA1c instruments ... sale. Drew has also identified an outsourcing partner for ... available for sale by the summer of 2012.  Drew ...
... Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today ... and chief executive officer, will present at the RBC Healthcare ... 10:30 a.m. Eastern Time.  Dr. Sands will provide an overview ... A live webcast of the presentation will be available through ...
Cached Medicine Technology:Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 2Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 3Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 4Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference 2
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... New research ... Click here to read more on the Surviving Mesothelioma website. , ... Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 and ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial ... birds from the AC units and ventilation systems on hospital roofs. Bird droppings can ... Nile virus. When these droppings dry, the fine powder can be carried into hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks to ... his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and ... “If we take responsibility for ourselves, we can create better realities.” His book illustrates ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After conducting ... , St. John’s Episcopal Hospital in Far Rockaway, N.Y., has hired Gerard ... , With more than 25 years of healthcare leadership experience, Walsh is an expert ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial ... implant, more commonly known as the “bionic eye,” researchers have determined the trial to ... tool for patients facing or already affected by complete vision loss as a result ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... SHANGHAI, China, Jan. 14 /PRNewswire-Asia-FirstCall/ -- China-Biotics, ... Company"), a leading Chinese firm,specializing in the ... products, today announced it has signed contracts,with ... Co., Ltd. ("Yuejia Food"),Shandong Huwa Dairy Industry ...
... Released as First Native ApplicationCHARLOTTESVILLE, Va., Jan. 14 ... a leader in knowledge management solutions for healthcare, ... download to Apple(R) iPhone(TM) and iPod(R) touch devices. ... for BlackBerry, Windows Mobile, and Palm OS devices ...
... 14 /PRNewswire/ -- Scarguard Labs, LLC, a ... and other dermatological problems through the use of multi-technology ... it has appointed Richard E. Pino as Chief Financial ... accounting, and treasury functions and will report to Chief ...
... Transfusion Service Software Confirms its Leading Position in ... Jan. 14 Global Med Technologies(R), Inc. ("Global ... an international e-Health, medical information technology company, today ... EgdeTrack* Transfusion Services Software (marketed as "Hemo Serveur" ...
... Number of people sickened in outbreak rises to 425 in ... -- As the number of people sickened by salmonella-contaminated peanut ... said Tuesday that one death in Minnesota and two in ... known for sure that the three people, whose names and ...
... Lagan, a provider of enterprise case management solutions that ... announced a new Lagan Human Services Call Center ... agencies in North America. The new solution is ... a range of functions depending on the programs administered, ...
Cached Medicine News:Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 2Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 3Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 4Health News:Unbound Medicine Announces Download Support for iPhone(TM) and iPod(R) Touch Devices 2Health News:Scarguard Labs, LLC Appoints Richard E. Pino as CFO 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Salmonella Linked to Deaths in Virginia, Minnesota 2Health News:Salmonella Linked to Deaths in Virginia, Minnesota 3Health News:Lagan Unveils Human Services Call Center Solution for North America 2
... The Elite II features ... proven University of Glasgow,(UG) algorithm. ... criteria to age, the UG,algorithm ... clinically,significant criteria: gender, age, race, ...
... face provides three contrast levels (high, 9.5 % ... 20/100. This test is designed to detect very ... contact lens evaluation or due to refractive surgery. ... the same contrast and acuity levels as the ...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
Medicine Products: